

February 4, 2026

Nano Holdings, Inc.
Atsushi Matsumura, Chairman, President & CEO
(4571 Tokyo Stock Exchange Growth Market)
URL: <https://www.nano-hd.com/en>

**Accelerated Integration of Experienced Executive Talent
Dr. Yasunori Yamaguchi Appointed as Chief Business Development Officer**

Nano Holdings, Inc. is a strategic investment company that provides integrated investment and value-creation support for unlisted venture companies and corporate carve-out businesses. We continue to accelerate our business growth as specialists with deep expertise in drug discovery, investment, and management join our team. The expansion of our unique value-creation investment model is steadily progressing.

We are pleased to announce that Dr. Yasunori Yamaguchi, who has an extensive track record across research, business development, and executive management in the global pharmaceutical industry—and who has led the creation of numerous businesses—has joined Nano Holdings as Chief Business Development Officer (CBDO).

Biography of Yasunori Yamaguchi, Ph.D.

- Served in multiple leadership roles across R&D, planning, and strategy at Kyowa Kirin, where he led international partnerships, business strategy development, and alliance management in the fields of antibody therapeutics and cell therapies.
- As CEO and President of Kyowa Kirin's U.S. subsidiaries (BioWa, Inc. / Kyowa Hakko Kirin California, Inc.), he oversaw global operations and drove organizational management and business value enhancement.
- At Axcelead, Inc., he led global business development (BD), contributing to the creation of strategic alliances and strengthening the company's business foundation.
- As President & CEO of IP Gaia Inc., he established a research and development network comprising 11 academic institutions and 35 pharmaceutical companies, creating a business model that enhances success probability from early drug discovery through out-licensing.

At Nano Holdings, he will contribute to the design of a robust business foundation that enables sustainable value creation through investment, M&A, carve-outs, and pipeline reconfiguration.

Comment from Dr. Yamaguchi, CBDO

"Leveraging the broad network I have cultivated with domestic and global pharmaceutical companies, academia, and investors, I will work to further develop NANO Group's unique investment model. By establishing a system that continuously generates new value-creation opportunities within the industry, I aim to strengthen the competitive advantage of the entire Group."